| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3028372 | Thrombosis Research | 2008 | 4 Pages |
Abstract
This first phase I study of plasmin (human) TAL 05-00018, infused into thrombosed HD grafts, documents safety at all doses and an effective thrombolytic dosage of 24Â mg indicating that further investigation into locally delivered plasmin is warranted.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Richard Shlansky-Goldberg,